A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC)

Renal Cell ◽

Phase Ii Study ◽

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2

Annals of Oncology ◽

10.1093/annonc/mds399 ◽

2012 ◽

Vol 23 ◽

pp. ix258 ◽

Cited By ~ 24

Author(s):

A. Ravaud ◽

C. Barrios ◽

Ö. Anak ◽

D. Pelov ◽

A. Louveau ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interferon Alfa ◽

First Line ◽

A Randomized Phase II Study of AGS‐16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma

The Oncologist ◽

10.1002/onco.13628 ◽

2020 ◽

Author(s):

Christian Kollmannsberger ◽

Toni K. Choueiri ◽

Daniel Y.C. Heng ◽

Saby George ◽

Fei Jie ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Previously Treated Patients ◽

Previously Treated

Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy

Annals of Oncology ◽

10.1093/annonc/mdy283.089 ◽

2018 ◽

Vol 29 ◽

pp. viii311-viii312

Author(s):

G. Procopio ◽

F. Cognetti ◽

R. Miceli ◽

M. Milella ◽

A. Mosca ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Circulating Biomarkers ◽

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.04.023 ◽

2017 ◽

Vol 15 (6) ◽

pp. 642-651.e1

Author(s):

Roberto Pili ◽

Opeyemi Jegede ◽

Michael A. Carducci ◽

Judith Manola ◽

David L. Groteluschen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Different Doses

Prognostic factors for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC): Results from the French randomized phase II study TORAVA.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e15118 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e15118-e15118 ◽

Cited By ~ 1

Author(s):

B. J. Escudier ◽

S. Negrier ◽

D. Perol ◽

G. Gravis ◽

R. Delva ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Progression Free Survival ◽

Free Survival ◽

A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.4525 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 4525-4525 ◽

Cited By ~ 9

Author(s):

Thomas Powles ◽

Stephane Oudard ◽

Bernard J. Escudier ◽

Janet Elizabeth Brown ◽

Robert E. Hawkins ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Annals of Oncology ◽

10.1093/annonc/mdv103 ◽

2015 ◽

Vol 26 (7) ◽

pp. 1372-1377 ◽

Cited By ~ 51

Author(s):

B.I. Rini ◽

B. Melichar ◽

M.N. Fishman ◽

M. Oya ◽

Y.K. Pithavala ◽

...

Keyword(s):

Blood Pressure ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Response ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Dose Titration ◽